Pfizer’s Mylotarg looks set for a return to the US market after FDA advisers recommended its use in acute myeloid leukaemia. The drug comes with a fascinating history, and in many ways was a ...

Vor Biopharma's trem-cel offers hope for AML treatment, but financial risks and early-stage progress suggest caution. Learn ...

Pfizer’s Mylotarg is back on the US market after a seven-year absence, after the FDA reapproved it in the aggressive blood cancer, acute myeloid leukaemia. The world’s first approved antibody ...

Clinical trial complexity, logistical challenges associated with treatments, and resource constraints at trial sites cited as top factors that delay enrollment into cell and gene therapy (CGT ...

Detailed price information for Vor Biopharma Inc (VOR-Q) from The Globe and Mail including charting and trades.

Antibodies and related products are the fastest growing class of therapeutic agents. By analysing the regulatory approvals of IgG-based biotherapeutic agents in the past 10 years, we can gain ...

the potential of trem-cel to enable targeted therapies in the post-transplant setting including Mylotarg and CD33-targeted CAR-Ts while maintaining healthy blood count levels and change the ...

In the second half of the same year, Vor plans to share updated data from the Phase 1/2a VBP101 trial of trem-cel in combination with Mylotarg. These are the recent developments at Vor Biopharma.

ADC药物还根据靶向的靶点数目分为单抗、双抗、多抗多种分类。抗体数目越多，疗效越广泛，但研发难度也更高。早期ADC药物（如Mylotarg）在临床试验中出现了严重的副作用，导致其在2010年被撤市。 但朱义坚定认为，百利天恒要做ADC。原因很简单，从原理上说 ...